Scorpius announced its collaboration with KaloCyte. Under this initial project, Scorpius will utilize its scientific and technical expertise to enhance manufacturing efficiencies for KaloCyte’s lead candidate, ErythroMer, a dried, bio-inspired artificial red blood cell designed to address life-threatening blood loss in situations where stored red blood cells are unavailable, unsuitable, or in short supply. The two companies are also evaluating opportunities to establish a commercial-scale manufacturing agreement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPX:
- Scorpius Holdings cancels planned 1-for-20 reverse stock split
- Scorpius Holdings Implements Reverse Stock Split Strategy
- Scorpius Holdings announces 1-for-20 reverse stock split
- Scorpius Holdings files to sell 29.41M shares of common stock, warrants
- Scorpius Holdings files to sell 47.4M shares of common stock for holders